Next Article in Journal
How p53 Molecules Solve the Target DNA Search Problem: A Review
Next Article in Special Issue
Chemoradiotherapy Increases Intratumor Heterogeneity of HPSE Expression in the Relapsed Glioblastoma Tumors
Previous Article in Journal
Human Pluripotent Stem Cells in Reproductive Science—A Comparison of Protocols Used to Generate and Define Male Germ Cells from Pluripotent Stem Cells
Previous Article in Special Issue
NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
Review

The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors

1
Department of Radiology & Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands
2
Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
3
Princess Máxima Center for Pediatric Oncology, 3584 CS Utrecht, The Netherlands
4
Department of Pediatrics, Amsterdam UMC, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(3), 1029; https://doi.org/10.3390/ijms21031029
Received: 6 January 2020 / Revised: 27 January 2020 / Accepted: 1 February 2020 / Published: 4 February 2020
(This article belongs to the Special Issue Molecular Biology of Brain Tumors)
This review highlights the added value of PET imaging in Central Nervous System (CNS) tumors, which is a tool that has rapidly evolved from a merely diagnostic setting to multimodal molecular diagnostics and the guidance of targeted therapy. PET is the method of choice for studying target expression and target binding behind the assumedly intact blood–brain barrier. Today, a variety of diagnostic PET tracers can be used for the primary staging of CNS tumors and to determine the effect of therapy. Additionally, theranostic PET tracers are increasingly used in the context of pharmaceutical and radiopharmaceutical drug development and application. In this approach, a single targeted drug is used for PET diagnosis, upon the coupling of a PET radionuclide, as well as for targeted (nuclide) therapy. Theranostic PET tracers have the potential to serve as a non-invasive whole body navigator in the selection of the most effective drug candidates and their most optimal dose and administration route, together with the potential to serve as a predictive biomarker in the selection of patients who are most likely to benefit from treatment. PET imaging supports the transition from trial and error medicine to predictive, preventive, and personalized medicine, hopefully leading to improved quality of life for patients and more cost-effective care. View Full-Text
Keywords: molecular biology; central nervous system; oncology; CNS tumors; positron emission tomography; PET; molecular imaging; targeted therapy; theranostics; drug development molecular biology; central nervous system; oncology; CNS tumors; positron emission tomography; PET; molecular imaging; targeted therapy; theranostics; drug development
Show Figures

Figure 1

MDPI and ACS Style

Pruis, I.J.; van Dongen, G.A.M.S.; Veldhuijzen van Zanten, S.E.M. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors. Int. J. Mol. Sci. 2020, 21, 1029. https://doi.org/10.3390/ijms21031029

AMA Style

Pruis IJ, van Dongen GAMS, Veldhuijzen van Zanten SEM. The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors. International Journal of Molecular Sciences. 2020; 21(3):1029. https://doi.org/10.3390/ijms21031029

Chicago/Turabian Style

Pruis, Ilanah J., Guus A.M.S. van Dongen, and Sophie E.M. Veldhuijzen van Zanten. 2020. "The Added Value of Diagnostic and Theranostic PET Imaging for the Treatment of CNS Tumors" International Journal of Molecular Sciences 21, no. 3: 1029. https://doi.org/10.3390/ijms21031029

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop